3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
3
Thoracic
2
Breast
2
Genitourinary
1
Gastrointestinal
1
Conditions
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
30
Carboplatin
13
Trastuzumab
8
Paclitaxel
7
Nivolumab
7
Cisplatin
6
Ipilimumab
5
Cetuximab
5
Bevacizumab
5
Taxes
4
Pemetrexed
4
Specimen Handling
3
Irinotecan
3
Docetaxel
3
Cyclophosphamide
3
Biopsy
3
tisotumab vedotin
2
temsirolimus
2
spartalizumab
2
sargramostim
2
pertuzumab
2
lenvatinib
2
fludarabine
2
epacadostat
2
enzalutamide
2
aldesleukin
2
X-Rays
2
Ritonavir
2
Psychiatric Rehabilitation
2
Oxaliplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
AZD5305
×
Thoracic
×
Clear all
NCT05797168
2026-06-03
FONTANA
AstraZeneca
Phase 1/2
Recruiting
506 enrolled
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled